Dyne Therapeutics to Participate in Upcoming Investor Conferences
Dyne Therapeutics (Nasdaq: DYN) said management will participate in several investor conferences in March 2026, including TD Cowen (fireside chat Mar 4), Jefferies Biotech on the Beach (meetings Mar 10–11) and Stifel Virtual CNS Forum (fireside chat Mar 17).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Dyne Therapeutics (Nasdaq: DYN) said management will participate in several investor conferences in March 2026, including TD Cowen (fireside chat Mar 4), Jefferies Biotech on the Beach (meetings Mar 10–11) and Stifel Virtual CNS Forum (fireside chat Mar 17).
Live webcasts of each fireside chat will be available on Dyne's Investors & Media site and replays accessible for 90 days.
Details
News Market Reaction – DYN
On Feb 25, the day this news came out, DYN closed 3.54% above the previous close.
Data tracked by StockTitan Argus for the Feb 25 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:
- TD Cowen 46th Annual Health Care Conference, fireside chat on Wednesday, March 4, 2026 at 11:50 a.m. ET in Boston, MA
- 2026 Jefferies Biotech on the Beach Summit, hosting meetings on Tuesday, March 10 and Wednesday, March 11, 2026 in Miami, FL
- Stifel 2026 Virtual CNS Forum, virtual fireside chat on Tuesday, March 17, 2026 at 4:00 p.m. ET
A live webcast of each fireside chat will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.
Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.